Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 2, 2012, Pages 474-483

  Salvatorelli, Emanuela ^a   Menna, Pierantonio ^a   Paz, Odalys Gonzalez ^a   Surapaneni, Sekhar ^b   Aukerman, Sharon L ^b   Chello, Massimo ^a   Covino, Elvio ^a   Sung, Victoria ^b   Minotti, Giorgio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACONITATE HYDRATASE; ALCOHOL; AMRUBICIN; DOXORUBICIN; EPIRUBICIN; HYDROGEN PEROXIDE; MITOCHONDRIAL ENZYME; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; ENZYME ASSAY; ENZYME INACTIVATION; EX VIVO STUDY; HEART MUSCLE FIBER MEMBRANE; HUMAN; HUMAN TISSUE; METABOLIC ACTIVATION; METABOLITE; OXIDATION REDUCTION REACTION; OXIDATIVE PHOSPHORYLATION UNCOUPLING; PHASE PARTITIONING; PRIORITY JOURNAL;

ACONITATE HYDRATASE; ALCOHOLS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CYTOPLASM; DOXORUBICIN; EPIRUBICIN; HUMANS; HYDROGEN PEROXIDE; MITOCHONDRIA; MYOCARDIUM; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; TROPONIN I;

EID: 84859953907     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190264     Document Type: Article

References (48)

1. Beinert H and Kennedy MC (1993) Aconitase, a two-faced protein: enzyme and iron regulatory factor. FASEB J 7:1442-1449. (Pubitemid 24003263)
2. Brazzolotto X, Andriollo M, Guiraud P, Favier A, and Moulis JM (2003) Interactions between doxorubicin and the human iron regulatory system. Biochim Biophys Acta 1593:209-218. (Pubitemid 36173489)
3. Cardinale D and Sandri MT (2010) Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 53:121-129.
4. Cartoni A, Menna P, Salvatorelli E, Braghiroli D, Giampietro R, Animati F, Urbani A, Del Boccio P, and Minotti G (2004) Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function for ferrylmyoglobin? J Biol Chem 279:5088-5099. (Pubitemid 38220525)
5. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ, and ASCO Cancer Survivorship Expert Panel (2007) American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 25:3991-4008. (Pubitemid 47477279)
6. Chance B, Sies H, and Boveris A (1979) Hydroperoxide metabolism in mammalian organs. Physiol Rev 59:527-605. (Pubitemid 9236599)
7. Davies KJ and Doroshow JH (1986) Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261:3060-3067. (Pubitemid 17204909)
8. Deng S, Kruger A, Kleschyov AL, Kalinowski L, Daiber A, and Wojnowski L (2007) Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radic Biol Med 42:466-473. (Pubitemid 46162116)
9. Gardner PR, Raineri I, Epstein LB, and White CW (1995) Superoxide radical and iron modulate aconitase activity in mammalian cells. J Biol Chem 270:13399-13405.
10. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
11. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, and Sawyer DB (2008) Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 26:3777-3784.
12. Gille L and Nohl H (1997) Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 23:775-782. (Pubitemid 27364872)
13. Goormaghtigh E, Huart P, Praet M, Brasseur R, and Ruysschaert JM (1990) Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 35:247-257. (Pubitemid 20185442)
14. Hausladen A and Fridovich I (1994) Superoxide and peroxynitrite inactivate aconitases, but nitric oxide does not. J Biol Chem 269:29405-29408. (Pubitemid 24365084)
15. Kalivendi SV, Kotamraju S, Zhao H, Joseph J, and Kalyanaraman B (2001) Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J Biol Chem 276:47266-47276.
16. Kurata T (2009) Amrubicin for the treatment of advanced lung cancer. Expert Opin Drug Metab Toxicol 5:171-180.
17. LeBel CP, Ischiropoulos H, and Bondy SC (1992) Evaluation of the probe 2′,7′- dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 5:227-231.
18. L'Ecuyer T, Allebban Z, Thomas R, and Vander Heide R (2004) Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am J Physiol Heart Circ Physiol 286:H2057-H2064. (Pubitemid 38685217)
19. Marcillat O, Zhang Y, and Davies KJ (1989) Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochem J 259:181-189. (Pubitemid 19100513)
20. Menna P, Gonzalez Paz O, Chello M, Covino E, Salvatorelli E, and Minotti G (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11:S21-S36.
21. Menna P, Salvatorelli E, and Minotti G (2007) Doxorubicin degradation in cardiomyocytes. J Pharmacol Exp Ther 322:408-419. (Pubitemid 46956366)
22. Menna P, Salvatorelli E, and Minotti G (2008) Cardiotoxicity of antitumor drugs. Chem Res Toxicol 21:978-989.
23. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004a) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229. (Pubitemid 38720829)
24. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, and Cairo G (2004b) Anticancer anthracyclines and the control of iron metabolism: quinine-dependent and independent mechanisms. Methods Enzymol 378:340-361.
25. Minotti G, Recalcati S, Mordente A, Liberi G, Calafiore AM, Mancuso C, Preziosi P, and Cairo G (1998) The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J 12:541-552. (Pubitemid 28183513)
26. Minotti G, Salvatorelli E, and Menna P (2010) Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther 334:2-8.
27. Narahari J, Ma R, Wang M, and Walden WE (2000) The aconitase function of iron regulatory protein 1. Genetic studies in yeast implicate its role in iron-mediated redox regulation. J Biol Chem 275:16227-16234. (Pubitemid 30366935)
28. Noguchi T, Ichii S, Morisada S, Yamaoka T, and Yanagi Y (1998) Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 89:1061-1066. (Pubitemid 28544783)
29. Ogawara D, Fukuda M, Nakamura Y, and Kohno S (2010) Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer. Cancer Manag Res 2:191-195.
30. Peng X, Chen B, Lim CC, and Sawyer DB (2005) The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanisms into preventative medicine. Mol Interv 5:163-171. (Pubitemid 41018273)
31. Powis G (1989) Free radical formation by antitumor quinones. Free Radic Biol Med 6:63-101.
32. Recalcati S, Minotti G, and Cairo G (2010) Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal 13:1593-1616.
33. Rota C, Fann YC, and Mason RP (1999) Phenoxyl free radical formation during the oxidation of the fluorescent dye 2′,7′- dichlorofluorescein by horseradish peroxidase. Possible consequences for oxidative stress measurements. J Biol Chem 274:28161-28168.
34. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, and Andersen PK (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100:1058-1067.
35. Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, Animati F, Goso C, Maggi CA, Manzini S, et al. (2003) Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary alcohol metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol 139:641-651. (Pubitemid 36819634)
36. Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggiò MA, Mordente A, Gianni L, and Minotti G (2006) Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281:10990-11001. (Pubitemid 43855522)
37. Salvatorelli E, Menna P, Gianni L, and Minotti G (2007) Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. J Pharmacol Exp Ther 320:790-800. (Pubitemid 46147961)
38. Salvatorelli E, Menna P, Lusini M, Covino E, and Minotti G (2009) Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart. J Pharmacol Exp Ther 329:175-184.
39. Salvatorelli E, Menna P, Surapaneni S, Aukerman SL, Chello M, Covino E. Sung V, and Minotti G (2012) Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin. J Pharmacol Exp Ther 341:464-473.
40. Simů nek T, Stérba M, Popelová O, Adamcová M, Hrdina R, and Gersl V (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154-171.
41. Sparagna GC and Lesnefsky EJ (2009) Cardiolipin remodeling in the heart. J Cardiovasc Pharmacol 53:290-301.
42. Stewart DJ, Grewaal D, Green RM, Mikhael N, Goel R, Montpetit VA, and Redmond MD (1993) Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res 13:1945-1952. (Pubitemid 24036310)
43. Stoscheck CM (1990) Quantitation of protein. Methods Enzymol 182:50-68.
44. van Dalen EC, Michiels EM, Caron HN, and Kremer LC (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 12:CD005006.
45. Vásquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, and Kalyanaraman B (1997) Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36:11293-11297. (Pubitemid 27408610)
46. Wallace KB (2003) Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93:105-115.
47. Xu R, Fisher M, and Juliano RL (2011) Targeted albumin-based nanoparticles for delivery of amphipathic drugs. Bioconjug Chem 22:870-878.
48. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, and Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067-1073. (Pubitemid 28544784)